1. < Prostate Cancer
Profile picture for kjbushur

Provenge, has anyone received this

Posted by kjbushur @kjbushur, Aug 16 6:51pm

I just completed paperwork for the treatment of Provenge. Paperwork was sent to my insurance for approval. My question is, has anyone received this treatment. My doctor said it should help to gain one or two additional years. What was your experience.
Best wishes for all of us to have best lives.

Interested in more discussions like this? Go to the Prostate Cancer Support Group.

Profile picture for jeff Marchi
jeff Marchi | @jeffmarc | Aug 16 8:30pm

I know a few people who have had Provenge. It’s good to have it when your PSA is still low. It is hoped that will give extra time. Actual results are a little hard to estimate.

In the IMPACT clinical trial, Provenge extended the median overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) by 4.1 months compared to placebo. The median survival in the Provenge group was 25.8 months versus 21.7 months in the control group.

REPLY
1 reply
Profile picture for Brettiquette
Brettiquette | @brettiquette | Aug 17 8:28am

Had a recent conversation with a client about our PC and he had the Provenge 12 years ago and had a 1900 PSA.
Still on Xtandi, about 70 now and undetectable. Amazing!

REPLY
1 reply
Profile picture for kjbushur
kjbushur | @kjbushur | Aug 17 6:20pm
In reply to @brettiquette "Had a recent conversation with a client about our PC and he had the Provenge 12..." + (show)
Profile picture for Brettiquette @brettiquette

Had a recent conversation with a client about our PC and he had the Provenge 12 years ago and had a 1900 PSA.
Still on Xtandi, about 70 now and undetectable. Amazing!

Jump to this post

Thank you for that information

REPLY
Profile picture for kjbushur
kjbushur | @kjbushur | Aug 17 6:23pm
In reply to @jeffmarc "I know a few people who have had Provenge. It’s good to have it when your..." + (show)
Profile picture for jeff Marchi @jeffmarc

I know a few people who have had Provenge. It’s good to have it when your PSA is still low. It is hoped that will give extra time. Actual results are a little hard to estimate.

In the IMPACT clinical trial, Provenge extended the median overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) by 4.1 months compared to placebo. The median survival in the Provenge group was 25.8 months versus 21.7 months in the control group.

Jump to this post

Thank you for your input.

REPLY
Please sign in or register to post a reply.